Kidney disease is linked to broad neutralizing deficits after China’s Omicron wave
Adults living with kidney disease entered the post-Omicron period with weaker serum neutralization against SARS-CoV-2 than healthy controls drawn from the same province and the same narrow calendar window. The gap was present against the prototype strain and persisted across two antigenically distinct Omicron variants, BA.4/5 and XBB.1.5. In practical terms, the renal population was not simply lagging on one viral target; its humoral response was broadly blunted across the viral sequence tested.
The study included 380 adults in Zhejiang Province, 183 with kidney disease and 197 healthy controls, sampled from March to early April 2023 after China’s large 2022–2023 Omicron wave. Neutralizing activity was measured with pseudovirus assays against three spike backgrounds, and results were expressed as 50% pseudovirus neutralization titers. The design matters because regional exposure, vaccination history, and recent infection can all shape antibody levels, yet the comparison here was anchored to the same population and the same post-wave period.
Against the prototype strain, the kidney disease group reached a geometric mean ratio of 0.167 versus controls, a steep deficit that signals far less functional antibody activity. The deficit was smaller but still significant for BA.4/5, with a ratio of 0.491, and remained evident for XBB.1.5 at 0.626. A single sentence captures the pattern: kidney disease tracked with lower neutralization every time the assay changed viral skin.
Sex-related heterogeneity was strongest in women
The most striking interaction involved sex. Group-by-sex effects were significant for all three viruses, and the relative control-versus-kidney disease gap was larger among women than among men. In a field that often focuses on disease category alone, this finding pushes the analysis closer to bedside reality: immune protection in kidney disease is not only attenuated, it is unevenly attenuated across sex.
Biologically, that pattern is plausible. Sex hormones, immune-cell trafficking, and vaccine responsiveness can shape B-cell maturation and antibody quality, and chronic kidney disease may amplify those differences through inflammation, uremic immune dysfunction, and treatment-related immune suppression in some patients. The study does not provide treatment-level data, so the mechanism cannot be assigned to any one drug or renal phenotype. Even so, the sex interaction suggests that the same clinical label of kidney disease may conceal different immune trajectories in men and women.
Booster history raised ancestral-strain titers, but not variant breadth
Vaccination history moved the ancestral-strain response in the expected direction. Receiving at least three doses, compared with zero to two doses, was associated with higher prototype titers in both groups. For BA.4/5 and XBB.1.5, however, the overall dose effect was not significant.
That pattern fits the antigenic distance between the original vaccine strain and later Omicron sublineages. Repeated exposure can widen the antibody pool, but immune imprinting and variant escape can still cap the breadth of neutralization. In a post-wave setting where many participants likely had both vaccination and prior infection, the absence of a strong dose association for the Omicron variants suggests that more doses did not fully overcome variant escape in this cohort.
The study also found no significant group interactions with age or vaccination-dose category. Age still matters clinically for immune reserve, but it did not explain the kidney disease gap here. The same held for vaccine-dose strata: the renal disadvantage persisted without a detectable modification by dose category.
Renal phenotype carried its own signal
Exploratory analyses separated kidney disease into broader phenotypic groups. Participants with glomerular or immune-mediated kidney disease had lower prototype and BA.4/5 titers than those with metabolic or vascular kidney disease. The comparison was exploratory, so it should be read as hypothesis-generating rather than definitive, but it points toward a real clinical possibility: the underlying renal disorder may shape immune competence as much as the label of kidney disease itself.
Immune-mediated renal disease often intersects with immunosuppressive therapy, systemic inflammation, and chronic antigen exposure. Metabolic and vascular kidney disease may carry a different immunologic burden. Because detailed medication data were unavailable, the analysis cannot separate disease biology from treatment effects, and that is the main limitation of the phenotype findings. Even so, the subgroup signal is consistent with a broader theme running through the paper: kidney disease is not immunologically uniform.
Prior infection lifted BA.4/5 titers without changing the group gap
Within the questionnaire subgroup, confirmed SARS-CoV-2 infection before sampling was associated with higher BA.4/5 titers. The interaction between infection status and study group was not significant, meaning prior infection improved responses without erasing the kidney disease–control difference. Recent infection likely served as a biological boost, but one that still operated within the constraints of impaired renal immunity.
This is the clinical tension at the center of the paper. Natural infection after a large Omicron wave can restore some neutralizing activity, yet the renal cohort remained disadvantaged overall. For clinicians caring for patients with chronic kidney disease, that means infection history cannot be assumed to normalize protection, even when antibody levels rise.
Post-wave immunity in kidney disease remains incomplete
The study’s strongest message is not about a single titer threshold. It is about the shape of immune deficit after a sweeping regional wave: lower neutralization across prototype and Omicron strains, a larger relative gap among women, and phenotype-specific differences that may reflect underlying immune biology. The findings argue for a more granular approach to renal populations, one that considers sex, kidney disease subtype, vaccination history, and prior infection together rather than in isolation.
Several limits keep the interpretation grounded. This was a cross-sectional study, so it cannot determine how quickly antibody levels fall or whether lower titers translated into clinical breakthrough infections. Individual immunosuppressive medication data were unavailable, and that leaves an important gap in causal explanation. Vaccination analyses also depended on linked records, and questionnaire-based infection history covered only a subgroup.
Even with those constraints, the message is direct. After China’s Omicron wave, kidney disease was associated with impaired neutralizing immunity against three SARS-CoV-2 variants, and the deficit was especially pronounced in women. Prospective work will need to connect these immune measures with renal phenotype, treatment exposure, and actual infection outcomes if the field is to move from serology to risk prediction.